64% of large firms say GLP-1 drug coverage moderately or significantly impacted their prescription drug spending Similar to the findings on use, 43% of firms with 1,000 to 4,999 workers, and 66% of firms with 5,000 or more workers, say that covering GLP-1 agonists for weight loss had a significant impact on the health plans prescription drug spending
That's a problem, since clinical data has shown that the majority of patients regain most of the weight they lost on a GLP-1 after they stop taking it
Thats already happening
doi:10.1210/jc.2015-1176 Hansen MS, Wlfel EM, Jeromdesella S, et al
If your system is underfed, overtrained, or inflamed, results may stall
Each pen is designed to deliver only the doses it is labeled for, and trying to exceed that dose will be inaccurate and may waste medication